Proliferative effect of Apidra® (insulin glulisine), a rapid-acting insulin analogue on mammary epithelial cells

The structural modification of insulin results in the generation of insulin analogues that show altered binding affinities to the insulin receptor and/or the IGF-I receptor, and as a consequence insulin analogues may have altered mitogenic potency. We analysed the proliferative effect of the rapid-acting insulin analogue Apidra® (insulin glulisine) on mammary epithelial cells. We show that Apidra and Actrapid® (recombinant human insulin) have similar proliferative effects on benign MCF10A and tumorigenic MCF7 cells and on epithelial cells of mouse mammary gland. Whereas Apidra and Actrapid induced similar activation of Erk1/2, activation of Akt/PKB by Apidra was significantly weaker compared to regular insulin. As AKT/PKB, an effector of the phosphoinositide 3-kinase pathway, mediates metabolic effects of insulin, we studied induction of hexokinase-2 in MCF7 cells and hexokinase-2 and hexokinase-4 in HepG2 cells by Actrapid and Apidra. Both genes were not significantly induced by Actrapid and Apidra in these cell lines.

[1]  C C Howe,et al.  Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. , 1980, Science.

[2]  J. Eckel,et al.  A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. , 2003, Diabetes.

[3]  J. Campisi,et al.  Ras proteins are essential and selective for the action of insulin-like growth factor 1 late in the G1 phase of the cell cycle in BALB/c murine fibroblasts. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[4]  V. Ehemann,et al.  Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. , 2009, Endocrine-related cancer.

[5]  F. Frasca,et al.  The role of insulin receptors and IGF-I receptors in cancer and other diseases , 2008, Archives of physiology and biochemistry.

[6]  H. Arnqvist,et al.  Mitogenic Effect of the Insulin Analogue Glargine in Malignant Cells in Comparison with Insulin and IGF-I , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[7]  Neil A. Reynolds,et al.  Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus. , 2004, Drugs.

[8]  A. Belfiore,et al.  IGF and Insulin Receptor Signaling in Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[9]  T. Ureta,et al.  Adaptive character of liver glucokinase , 1975, Molecular and Cellular Biochemistry.

[10]  R. Becker.  Insulin glulisine complementing basal insulins: a review of structure and activity. , 2007, Diabetes technology & therapeutics.

[11]  Tom L. Blundell,et al.  Insulin: The Structure in the Crystal and its Reflection in Chemistry and Biology by , 1972 .

[12]  B. van der Burg,et al.  Mitogenic Signaling of Insulin-like Growth Factor I in MCF-7 Human Breast Cancer Cells Requires Phosphatidylinositol 3-Kinase and Is Independent of Mitogen-activated Protein Kinase* , 1997, The Journal of Biological Chemistry.

[13]  Saroj P. Mathupala,et al.  Aberrant Glycolytic Metabolism of Cancer Cells: A Remarkable Coordination of Genetic, Transcriptional, Post-translational, and Mutational Events That Lead to a Critical Role for Type II Hexokinase , 1997, Journal of bioenergetics and biomembranes.

[14]  L. Schäffer,et al.  Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. , 2000, Diabetes.

[15]  T. Bartels,et al.  Insulin Glulisine—A Comprehensive Preclinical Evaluation , 2006, International journal of toxicology.

[16]  H. Klein,et al.  Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. , 1996, The Biochemical journal.

[17]  D. Mayer,et al.  Glycogen Synthase Kinase-3 Interacts with and Phosphorylates Estrogen Receptor and Is Involved in the , 2005 .

[18]  H. Soule,et al.  Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. , 1973, The Journal of biological chemistry.

[19]  A. Benner,et al.  Down‐regulation of insulin‐like growth factor‐I receptor and insulin receptor substrate‐1 expression in advanced human breast cancer , 2000, International journal of cancer.

[20]  D. Mayer,et al.  Proliferative effects of insulin analogues on mammary epithelial cells. , 2008, Archives of physiology and biochemistry.

[21]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[22]  A. Vølund,et al.  Insulin analogs with improved pharmacokinetic profiles. , 1999, Advanced drug delivery reviews.

[23]  J. Olefsky,et al.  Insulin and insulin-like growth factor-I signal transduction requires p21ras. , 1994, The Journal of biological chemistry.

[24]  D. Mayer,et al.  Microheterogeneity of cytosolic and membrane-bound hexokinase II in Morris hepatoma 3924A. , 1994, The Biochemical journal.

[25]  D. McTavish,et al.  Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. , 1997, Drugs.

[26]  W. Duckworth,et al.  Genetically engineered insulin analogs: diabetes in the new millenium. , 2000, Pharmacological reviews.

[27]  V. Strack,et al.  Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors , 2005, Diabetologia.

[28]  S. Gammeltoft,et al.  Insulin aspart: a novel rapid-acting human insulin analogue. , 1999, Expert opinion on investigational drugs.

[29]  V. Steele,et al.  Induction and prevention of carcinogen-induced precancerous lesions in mouse mammary gland organ culture , 1997 .

[30]  L. Slieker,et al.  Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor , 1997, Diabetologia.

[31]  D. Mayer,et al.  Glycogen synthase kinase-3 protects estrogen receptor alpha from proteasomal degradation and is required for full transcriptional activity of the receptor. , 2007, Molecular endocrinology.

[32]  D. Mayer,et al.  Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages. , 1994, Biochimica et biophysica acta.